LilyMir Posted September 12, 2022 Share Posted September 12, 2022 Great results from ADAURA Phase III trial (Tagrisso for adjuvant use following full resection with negative margins). Mainly: ~3 in 4 patients treated with adjuvant Tagrisso were alive and disease-free at 4 years. Tagrisso also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease. "Tagrisso demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer": https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html#! Other reports on same: https://www.yalecancercenter.org/news-article/adaura-trial-results-provide-new-hope-for-patients-with-early-stage-non-small-cell-lung-cancer/ https://www.onclive.com/view/updated-adaura-data-reinforce-adjuvant-osimertinib-as-soc-for-egfr-mutated-stage-ib-iiia-nsclc Hurrah! Tom Galli and Judy M2 2 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.